ADMA Biologics Inc vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? ADMA Biologics Inc trades at $9.86 (market cap $2.22B), while Direxion Daily Semiconductor Bull 3X Shares trades at $144. The key difference: Direxion Daily Semiconductor Bull 3X Shares is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | SOXL | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $20.38 | $300.77 |
52-Week Low | $7.60 | $24.91 |
Enterprise Value | $2.29B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
SOXL, the Direxion Daily Semiconductor Bull 3X Shares ETF, surged 13.02% to $146.92 amid renewed semiconductor sector optimism. The leveraged ETF remains in a technical bearish trend despite the recent rally, with moving averages signaling continued downward pressure. Recent news highlights significant government semiconductor funding and AI-driven demand catalysts, though the fund has experienced extreme volatility, dropping over 60% from its peak earlier this year before this rebound.
The outlook remains volatile with leveraged exposure amplifying both gains and losses. Investment opportunity exists for aggressive investors betting on sustained semiconductor recovery and AI infrastructure spending, but risks include extreme volatility decay, sector concentration, and macroeconomic sensitivity. The current technical setup suggests cautious entry near support levels may offer better risk-reward positioning.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →